Kintara Therapeutics Inc. Stock News

If you really want to take a walk on the wild side, there are several stocks to buy under $5. But be prepared for unpredictability.

Kintara Therapeutics Inc (NASDAQ:KTRA) (OTCMKTS:DMPWW) (FRA:3DM), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, has announced its addition to the Russell

SAN DIEGO, June 7, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap

12:30pm: Nasdaq finds little upward momentum The Dow clawed its way out of an early deficit to 15 points higher at midday at 34,615. The Nasdaq was down 117 points, 0.9%, at 13,641, and the S&P 500 sh

Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) announced it has enrolled the final patient in the adjuvant arm of its ongoing Phase 2 clinical study of VAL-083 as a treatment for glioblastoma multif

SAN DIEGO, June 3, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap

SAN DIEGO, June 2, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that Chi

The stock price of Kintara Therapeutics, Inc. (Nasdaq: KTRA) increased by over 25% during intraday trading. This is why it happened.

Kintara Therapeutics, Inc. (NASDAQ:KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma mult

Kintara Therapeutics, Inc. (NASDAQ:KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma mult

SAN DIEGO, May 26, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap

Analysts at Aegis Capital Corp rated Kintara Therapeutics Inc (NASDAQ:KTRA) a 'Buy,' while maintaining a $7 share target price on the company which develops new solid tumor cancer therapies. The San D

Kintara Therapeutics Inc (NASDAQ:KTRA), which is focused on the development of new solid tumor cancer therapies, said it closed its fiscal third quarter with cash and cash equivalents of about $15.7 m

SAN DIEGO, May 14, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap

Kintara Therapeutics Inc (NASDAQ:KTRA) has announced the appointment of corporate finance veteran Tamara Seymour to its board of directors. Seymour replaces John Liatos, who will continue in his role